Symbols / GENB Stock $11.97 -7.71% Generate Biomedicines, Inc.

Healthcare • Biotechnology • United States • NMS
GENB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Michael T. Nally M.B.A.
Exch · Country NMS · United States
Market Cap 1.53B
Enterprise Value 1.08B
Income -265.44M
Sales 30.30M
FCF (ttm) —
Book/sh -12.24
Cash/sh 4.03
Employees 312
Insider 10d —
IPO Feb 27, 2026
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.80
PEG —
P/S 50.64
P/B -0.98
P/C —
EV/EBITDA -4.55
EV/Sales 35.76
Quick Ratio 8.85
Current Ratio 9.17
Debt/Eq 12.74
LT Debt/Eq —
EPS (ttm) -2.07
EPS next Y -2.06
EPS Growth —
Revenue Growth -18.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA —
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin -8.87%
Profit Margin 0.00%
Shs Outstand 128.19M
Shs Float 60.29M
Insider Own 23.14%
Instit Own 71.75%
Short Float 4.63%
Short Ratio 9.23
Short Interest 3.45M
52W High 16.75
vs 52W High -28.54%
52W Low 11.00
vs 52W Low 8.82%
Beta —
Impl. Vol. —
Rel Volume 2.33
Avg Volume 519.08K
Volume 1.21M
Target (mean) $25.40
Tgt Median $25.00
Tgt Low $22.00
Tgt High $30.00
# Analysts 5
Recom None
Prev Close $12.97
Price $11.97
Change -7.71%
About

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$25.40
Mean price target
2. Current target
$11.97
Latest analyst target
3. DCF / Fair value
$25.40
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$11.97
Low
$22.00
High
$30.00
Mean
$25.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-14 main Morgan Stanley Overweight → Overweight $22
2026-05-08 main HC Wainwright & Co. Buy → Buy $25
2026-04-13 init HC Wainwright & Co. — → Buy $16
2026-03-24 init Goldman Sachs — → Buy $26
2026-03-24 init Morgan Stanley — → Overweight $20
2026-03-24 init Piper Sandler — → Overweight $24
2026-03-24 init Cantor Fitzgerald — → Overweight —
2026-03-24 init Guggenheim — → Buy $30
News
RSS: Latest GENB news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31
Total Revenue
31.89
+55.89%
20.46
Operating Revenue
31.89
+55.89%
20.46
Operating Expense
266.96
+22.80%
217.40
Research And Development
224.70
+28.17%
175.31
Selling General And Administration
42.26
+0.41%
42.09
General And Administrative Expense
42.26
+0.41%
42.09
Salaries And Wages
28.09
+0.80%
27.86
Other Gand A
14.17
-0.35%
14.22
Total Expenses
266.96
+22.80%
217.40
Operating Income
-235.06
-19.36%
-196.94
Total Operating Income As Reported
-235.06
-19.36%
-196.94
EBITDA
-208.49
-27.36%
-163.71
Normalized EBITDA
-208.23
-27.38%
-163.47
Reconciled Depreciation
13.18
-14.14%
15.35
EBIT
-221.67
-23.80%
-179.05
Total Unusual Items
-0.26
-12.45%
-0.23
Total Unusual Items Excluding Goodwill
-0.26
-12.45%
-0.23
Net Income
-203.15
-16.91%
-173.77
Pretax Income
-222.80
-22.98%
-181.17
Net Non Operating Interest Income Expense
12.53
-21.72%
16.00
Interest Expense Non Operating
1.14
-46.36%
2.12
Net Interest Income
12.53
-21.72%
16.00
Interest Expense
1.14
-46.36%
2.12
Interest Income Non Operating
13.66
-24.60%
18.12
Interest Income
13.66
-24.60%
18.12
Other Income Expense
-0.26
-12.45%
-0.23
Gain On Sale Of Security
-0.26
-12.45%
-0.23
Tax Provision
0.16
-23.11%
0.21
Tax Rate For Calcs
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.06
-12.45%
-0.05
Net Income Including Noncontrolling Interests
-222.97
-22.92%
-181.38
Net Income From Continuing Operation Net Minority Interest
-203.15
-16.91%
-173.77
Net Income From Continuing And Discontinued Operation
-203.15
-16.91%
-173.77
Net Income Continuous Operations
-222.97
-22.92%
-181.38
Minority Interests
19.81
+160.23%
7.61
Normalized Income
-202.95
-16.91%
-173.59
Net Income Common Stockholders
-249.52
-16.72%
-213.78
Diluted EPS
-2.18
-4.33%
-2.09
Basic EPS
-2.18
-4.33%
-2.09
Basic Average Shares
102.31
+0.00%
102.31
Diluted Average Shares
102.31
+0.00%
102.31
Diluted NI Availto Com Stockholders
-249.52
-16.72%
-213.78
Preferred Stock Dividends
46.37
+15.91%
40.01
Line Item Trend 2025-12-31 2024-12-31
Total Assets
330.18
-36.29%
518.26
Current Assets
234.37
-42.49%
407.49
Cash Cash Equivalents And Short Term Investments
221.50
-43.73%
393.63
Cash And Cash Equivalents
121.65
-30.99%
176.27
Other Short Term Investments
99.85
-54.06%
217.36
Receivables
0.00
-100.00%
0.31
Accounts Receivable
0.00
-100.00%
0.31
Restricted Cash
0.34
-76.24%
1.43
Other Current Assets
12.53
+3.29%
12.13
Total Non Current Assets
95.82
-13.50%
110.77
Net PPE
89.01
-11.93%
101.07
Gross PPE
137.27
+0.75%
136.24
Accumulated Depreciation
-48.26
-37.20%
-35.17
Properties
0.00
0.00
Machinery Furniture Equipment
5.54
+1.02%
5.48
Construction In Progress
4.11
+363.32%
0.89
Other Properties
117.97
-1.90%
120.25
Leases
9.66
+0.36%
9.63
Other Non Current Assets
6.81
-29.84%
9.70
Total Liabilities Net Minority Interest
953.38
+0.00%
953.35
Current Liabilities
82.20
-5.11%
86.63
Payables And Accrued Expenses
29.57
+152.76%
11.70
Payables
3.84
-32.29%
5.67
Accounts Payable
3.84
-32.29%
5.67
Current Accrued Expenses
25.74
+326.55%
6.03
Pensionand Other Post Retirement Benefit Plans Current
13.80
+3.35%
13.35
Current Debt And Capital Lease Obligation
15.01
-10.22%
16.72
Current Capital Lease Obligation
15.01
-10.22%
16.72
Current Deferred Liabilities
21.19
-50.04%
42.42
Current Deferred Revenue
21.19
-50.04%
42.42
Other Current Liabilities
2.63
+8.06%
2.43
Total Non Current Liabilities Net Minority Interest
871.18
+0.51%
866.72
Long Term Debt And Capital Lease Obligation
53.52
-11.18%
60.26
Long Term Capital Lease Obligation
53.52
-11.18%
60.26
Non Current Deferred Liabilities
4.51
-70.27%
15.17
Non Current Deferred Revenue
4.51
-70.27%
15.17
Other Non Current Liabilities
0.12
-66.76%
0.35
Preferred Securities Outside Stock Equity
811.83
+2.78%
789.85
Stockholders Equity
-615.97
-41.76%
-434.52
Common Stock Equity
-615.97
-41.76%
-434.52
Capital Stock
0.03
+0.00%
0.03
Common Stock
0.03
+0.00%
0.03
Share Issued
127.45
+0.00%
127.45
Ordinary Shares Number
127.45
+0.00%
127.45
Additional Paid In Capital
60.19
+56.46%
38.47
Retained Earnings
-676.29
-42.94%
-473.14
Gains Losses Not Affecting Retained Earnings
0.11
-10.17%
0.12
Minority Interest
-7.23
-1166.55%
-0.57
Other Equity Adjustments
0.11
-10.17%
0.12
Total Equity Gross Minority Interest
-623.20
-43.23%
-435.09
Total Capitalization
-615.97
-41.76%
-434.52
Working Capital
152.16
-52.58%
320.87
Invested Capital
-615.97
-41.76%
-434.52
Total Debt
68.53
-10.97%
76.97
Capital Lease Obligations
68.53
-10.97%
76.97
Net Tangible Assets
-615.97
-41.76%
-434.52
Tangible Book Value
-615.97
-41.76%
-434.52
Derivative Product Liabilities
1.21
+10.35%
1.09
Line Item Trend 2025-12-31 2024-12-31
Operating Cash Flow
-200.62
-70.38%
-117.75
Cash Flow From Continuing Operating Activities
-200.62
-70.38%
-117.75
Net Income From Continuing Operations
-222.97
-22.92%
-181.38
Depreciation Amortization Depletion
13.18
-14.14%
15.35
Depreciation And Amortization
13.18
-14.14%
15.35
Other Non Cash Items
5.94
-1.08%
6.01
Stock Based Compensation
20.58
+5.71%
19.46
Operating Gains Losses
0.05
-65.97%
0.14
Gain Loss On Investment Securities
0.11
-26.62%
0.15
Gain Loss On Sale Of PPE
-0.06
-540.00%
-0.01
Change In Working Capital
-14.62
-151.98%
28.12
Change In Receivables
0.31
+244.60%
-0.21
Changes In Account Receivables
0.31
+244.60%
-0.21
Change In Prepaid Assets
-0.17
+96.91%
-5.38
Change In Payables And Accrued Expense
15.24
+93.75%
7.87
Change In Accrued Expense
17.37
+297.67%
4.37
Change In Payable
-2.13
-160.87%
3.50
Change In Account Payable
-2.13
-160.87%
3.50
Change In Other Working Capital
-31.89
-192.34%
34.54
Change In Other Current Assets
4.83
+238.18%
-3.50
Change In Other Current Liabilities
-2.94
+43.41%
-5.20
Investing Cash Flow
116.77
+302.28%
-57.73
Cash Flow From Continuing Investing Activities
116.77
+302.28%
-57.73
Net PPE Purchase And Sale
-3.51
-2.24%
-3.44
Purchase Of PPE
-3.51
-1.94%
-3.45
Sale Of PPE
0.00
-100.00%
0.01
Capital Expenditure
-3.51
-1.94%
-3.45
Net Investment Purchase And Sale
120.28
+321.56%
-54.29
Purchase Of Investment
-164.73
+41.79%
-282.98
Sale Of Investment
285.01
+24.63%
228.69
Financing Cash Flow
28.06
-69.28%
91.33
Cash Flow From Continuing Financing Activities
28.06
-69.28%
91.33
Net Issuance Payments Of Debt
-8.16
+26.64%
-11.12
Repayment Of Debt
-8.16
+26.64%
-11.12
Long Term Debt Payments
-8.16
+26.64%
-11.12
Net Long Term Debt Issuance
-8.16
+26.64%
-11.12
Proceeds From Stock Option Exercised
1.10
-2.66%
1.13
Net Other Financing Charges
13.15
+163.00%
5.00
Changes In Cash
-55.79
+33.70%
-84.15
Beginning Cash Position
181.83
-31.64%
265.98
End Cash Position
126.04
-30.68%
181.83
Free Cash Flow
-204.13
-68.43%
-121.20
Amortization Of Securities
-2.78
+48.92%
-5.45
Issuance Of Capital Stock
21.97
-77.19%
96.32
Net Preferred Stock Issuance
21.97
-77.19%
96.32
Preferred Stock Issuance
21.97
-77.19%
96.32
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category